Voriconazole News and Research

RSS

Voriconazole is a drug that treats infections caused by fungi.

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa.

8 Oct 2014

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.

8 Sep 2014

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection.

17 Jul 2014

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients.

9 Jul 2014

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).

12 Jun 2014

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain.

15 May 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.

4 Dec 2013

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

Mylan Pharmaceuticals launches Voriconazole for Oral Suspension

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole for Oral Suspension, 40 mg/mL, which is the first generic version of Pfizer's VFEND for Oral Suspension.

30 Sep 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

FDA approves Arbor Pharmaceuticals' NDA for Nymalize oral solution

Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved its New Drug Application for Nymalize (nimodipine) oral solution.

14 May 2013

Nearly 5 million asthmatics with ABPA could benefit from antifungal treatment, say researchers

An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from the University of Toronto and Manchester University.

9 May 2013

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg.

4 May 2013

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Lessons can be learnt from US fungal meningitis outbreak

As the current outbreak of fungal meningitis caused by contaminated methylprednisolone acetate injections continues to spread across the USA, past experience suggests that lessons can be learnt, says a US researcher.

24 Oct 2012

NEJM report on best options for safe, effective patient treatment against fungal meningitis

As the number of fungal meningitis cases continues to rise, physicians across the country are faced with how best to provide the early treatment that can save lives.

24 Oct 2012

Physician shares lessons learned from fungal meningitis outbreak

In a new perspective piece being published Online First tonight in Annals of Internal Medicine, a physician recalls lessons learned from treating patients affected by the 2002 outbreak of Exophiala (Wangiella) dermatitidis meningitis or arthritis related to contaminated, injectable coticosteroids prepared from a compounding pharmacy.

20 Oct 2012

Antifungal resistance of Candida genital isolates on the increase

Resistance to antifungal therapy of genital-infection causing Candida species may be an increasing problem, suggests research presented at the European Academy of Dermatology and Venereology annual congress in Prague, Czech Republic.

3 Oct 2012

Antifungal resistance of Candida genital isolates on the increase

2 Oct 2012

Voriconazole News and Research

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Mylan Pharmaceuticals launches Voriconazole for Oral Suspension

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

FDA approves Arbor Pharmaceuticals' NDA for Nymalize oral solution

Nearly 5 million asthmatics with ABPA could benefit from antifungal treatment, say researchers

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Lessons can be learnt from US fungal meningitis outbreak

NEJM report on best options for safe, effective patient treatment against fungal meningitis

Physician shares lessons learned from fungal meningitis outbreak

Antifungal resistance of Candida genital isolates on the increase

Antifungal resistance of Candida genital isolates on the increase

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News